Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;41(7):1694-1698.
doi: 10.1111/liv.14949. Epub 2021 May 28.

Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER)

Tangui Barré  1 , Clémence Ramier  1 , Vincent Di Beo  1 , Fabrice Carrat  2   3 , Hélène Fontaine  4   5 , Fabienne Marcellin  1 , Patrizia Carrieri  1 , Stanislas Pol  6 , Camelia Protopopescu  1 ; ANRS/AFEF Hepather study group
Collaborators, Affiliations
Free article
Comment

Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER)

Tangui Barré et al. Liver Int. 2021 Jul.
Free article
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Ciancio A, Ribaldone DG, Dotta A, et al. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. Liver Int. 2021;41:276-287.
    1. Huang T-S, Lin C-L, Lu M-J, et al. Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: a population-based cohort study. J Gastroenterol Hepatol. 2017;32:1355-1362.
    1. Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology. 2014;60:823-831.
    1. Butt AA, Yan P, Shuaib A, Abou-Samra A-B, Shaikh OS, Freiberg MS. Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events. Gastroenterology. 2019;156:987-996.e8.
    1. Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2017;66:39-47.

MeSH terms

Substances

Associated data